Atypical Hemolytic Uremic Syndrome (aHUS) manifests by chronic uncontrolled complement activation leading to the continuous activation of platelets and endothelial cells. The resulting thrombi cause thrombotic microangiopathy which may result in sudden fatal thrombotic complications or in the progressive failure of vital organs, including the kidney, heart, and brain. For Alexion Pharmaceuticals.